Marinus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Elemer Piros started Marinus Pharmaceuticals with an Overweight rating and $19 price target. The analyst views the stock’s risk/reward as compelling into upcoming data catalysts for ganaxolone, a positive allosteric modulator of GABAA receptor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.